As the drug plan landscape evolves, the nuanced tension between cost management and the imperative to support employee health continues, according to a panel of experts discussing Benefits Canada’s inaugural Drug Plan Opinion Survey during the 2025 Face to Face Drug Plan Management Forum. The survey, which polled 124 Canadian plan sponsors with at least […]
As dermatological treatments move up the ranking of conditions with the highest paid drug claims, they’ve become increasingly significant for private drug plan sponsors, according to Frances Lehun, a pharmacist with pharmaceutical expertise in high-cost drug management at Beneva. During a session at the 2025 Face to Face Drug Plan Management Forum, she said this […]
Private benefits plan sponsors’ spending on weight-management drugs has quadrupled since 2021, according to a new report by Telus Health. In 2024 alone, the category doubled in size, ranking No. 17 overall by eligible amount (up from No. 29 in 2023). Still, the category’s budget impact remains low. By the end of June 2025, the […]
As effective weight management drugs come to market, it’s time to move beyond outdated approaches to obesity care and towards holistic treatment strategies, said Marie-Hélène Dugal, national pharmacy strategy lead for Medavie Blue Cross, during Benefits Canada’s 2025 Toronto Benefits Summit. Obesity is a progressive, relapsing and complex chronic disease characterized by abnormal and excessive […]
Canadian employees who are on long-term disability leave are two-times more likely to claim for a chronic disease medication related to a secondary condition and three-times more likely to claim for medication treating two or more symptoms than those who aren’t on LTD, according to a new report by Sun Life Financial Inc. The report […]